|
PPP5C expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.023200000283E-07 |
| Normal-vs-Stage3 |
1.66999747364116E-12 |
| Normal-vs-Stage4 |
2.07944772512292E-13 |
| Stage1-vs-Stage2 |
3.558400E-01 |
| Stage1-vs-Stage3 |
9.843900E-02 |
| Stage1-vs-Stage4 |
1.434780E-01 |
| Stage2-vs-Stage3 |
8.047000E-01 |
| Stage2-vs-Stage4 |
7.339900E-02 |
| Stage3-vs-Stage4 |
1.148160E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
1.487299999825E-07 |
| Normal-vs-Asian |
1.77113879118451E-12 |
| Caucasian-vs-AfricanAmerican |
6.761100E-03 |
| Caucasian-vs-Asian |
1.254460E-02 |
| AfricanAmerican-vs-Asian |
4.984600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
7.301200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(61-80Yrs) |
4.00035560232936E-12 |
| Normal-vs-Age(81-100Yrs) |
2.280000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.707200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.718100E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.657000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.153240E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.652400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.496400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.216400E-01 |
| Classical-VS-Follicular |
1.481580E-02 |
| Classical-VS-Other |
5.422200E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
5.331000E-01 |
| Tall-VS-Other |
9.867400E-01 |
| Tall-VS-Normal |
2.720899999753E-07 |
| Follicular-VS-Other |
7.644800E-01 |
| Follicular-VS-Normal |
6.39730002305328E-09 |
| Other-VS-Normal |
3.838400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
3.00140001741056E-09 |
| N0-vs-N1 |
8.341800E-01 |
|
|
